Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jul;74(7):398-405.
doi: 10.1111/pcn.13016. Epub 2020 May 26.

Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial

Sara Momtazmanesh  1 , Zeinab Amirimoghaddam-Yazdi  1 , Hossein Sanjari Moghaddam  1 , Mohammad Reza Mohammadi  1 , Shahin Akhondzadeh  1
Affiliations
Free article
Randomized Controlled Trial

Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial

Sara Momtazmanesh et al. Psychiatry Clin Neurosci. 2020 Jul.
Free article

Abstract

Aim: Irritability related to autism spectrum disorder (ASD) complicates the management of ASD patients at home and in clinical settings. In this randomized, double-blind, placebo-controlled clinical trial, we aimed to investigate the beneficial effects of adjuvant treatment with risperidone and sulforaphane in alleviating the irritability of children with ASD.

Methods: Sixty drug-free patients aged 4-12 years were randomly assigned to one of two groups receiving risperidone plus sulforaphane or placebo. Risperidone was started with a daily dose of 0.25 mg in patients weighing <20 kg and 0.5 mg in those weighing ≥20 kg and increased stepwise to reach a maximum of 1 mg (<20 kg), 2.5 mg (20-45 kg), and 3.5 mg (>45 kg). Sulforaphane was administered at a daily dose of 50 μmol (≤45 kg) or 100 μmol (>45 kg). The participants were assessed with the Aberrant Behavior Checklist - Community Edition at baseline and at Weeks 5 and 10.

Results: Compared to the placebo group, ASD patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008). However, no difference was seen in improvements in the other secondary measures: Lethargy/Social Interaction score, Stereotypic Behavior score, Inappropriate Speech score, and frequency of adverse events.

Conclusion: Our results support the safety and efficacy of sulforaphane as an adjuvant to risperidone for improvement of irritability and hyperactivity symptoms in children with ASD.

Keywords: autism spectrum disorder; irritability; oxidative stress; risperidone; sulforaphane.

PubMed Disclaimer

References

    1. Christensen DL, Baio J, Van Naarden BK et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years: Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2012. MMWR Surveill. Summ. 2016; 65: 1-23.
    1. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol. Med. 2015; 45: 601-613.
    1. Mukherjee SB. Autism spectrum disorders: Diagnosis and management. Indian J. Pediatr. 2017; 84: 307-314.
    1. Charman T, Jones CR, Pickles A, Simonoff E, Baird G, Happe F. Defining the cognitive phenotype of autism. Brain Res. 2011; 1380: 10-21.
    1. Helverschou SB, Bakken TL, Martinsen H. Psychiatric disorders in people with autism spectrum disorders: Phenomenology and recognition. In: Matson JL, Sturmey P (eds). International Handbook of Autism and Pervasive Developmental Disorders. Springer, New York, NY, 2011; 53-74.

Publication types

MeSH terms